Details for New Drug Application (NDA): 204760

✉ Email this page to a colleague

NDA 204760 describes MOVANTIK, which is a drug marketed by Valinor and is included in one NDA. It is available from three suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the MOVANTIK profile page.

The generic ingredient in MOVANTIK is naloxegol oxalate. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the naloxegol oxalate profile page.

Summary for 204760

Tradename:	MOVANTIK
Applicant:	Valinor
Ingredient:	naloxegol oxalate
Patents:	2

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 204760

Generic Entry Date for 204760^: ⤷ Try for Free* Constraining patent/regulatory exclusivity: 9,012,469 Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 204760

Mechanism of Action	Opioid Antagonists

Suppliers and Packaging for NDA: 204760

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760	NDA	Quality Care Products, LLC	55700-988	55700-988-30	30 TABLET, FILM COATED in 1 BOTTLE (55700-988-30)
MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760	NDA	RedHill Biopharma Ltd	57841-1300	57841-1300-1	30 TABLET, FILM COATED in 1 BOTTLE (57841-1300-1)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	EQ 12.5MG BASE
Approval Date:	Sep 16, 2014	TE:		RLD:	Yes
Patent:	7,786,133	Patent Expiration:	Sep 16, 2028	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patent:	9,012,469	Patent Expiration:	Apr 2, 2032	Product Flag?	Y	Substance Flag?	Y	Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	EQ 25MG BASE
Approval Date:	Sep 16, 2014	TE:		RLD:	Yes
Patent:	7,786,133	Patent Expiration:	Sep 16, 2028	Product Flag?	Y	Substance Flag?	Y	Delist Request?

Expired US Patents for NDA 204760

Show entries

Subscribe to access the full database, or Try for Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Valinor	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014	8,617,530	⤷ Try for Free
Valinor	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014	7,056,500	⤷ Try for Free
Valinor	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014	7,662,365	⤷ Try for Free
Valinor	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014	7,056,500	⤷ Try for Free
Valinor	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014	8,067,431	⤷ Try for Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Showing 1 to 5 of 5 entries

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.